Nanotechnology-based drug delivery for central nervous system disorders.
Biomed Pharmacother
; 143: 112117, 2021 Nov.
Article
em En
| MEDLINE
| ID: mdl-34479020
ABSTRACT
Drug delivery to central nervous system (CNS) diseases is very challenging since the presence of the innate blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier that impede drug delivery. Among new strategies to overcome these limitations and successfully deliver drugs to the CNS, nanotechnology-based drug delivery platform, offers potential therapeutic approach for the treatment of some common neurological disorders like Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease. This review aimed to highlight advances in research on the development of nano-based therapeutics for their implications in therapy of CNS disorders. The challenges during clinical translation of nanomedicine from bench to bed side is also discussed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Portadores de Fármacos
/
Fármacos do Sistema Nervoso Central
/
Doenças do Sistema Nervoso Central
/
Nanomedicina
/
Nanopartículas
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article